Prof. Dr. Serdar Turhal, lisans öncesi öğrenimlerinin ardından İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi'nde başladığı tıp eğitimini başarıyla tamamlayarak tıp doktoru unvanı almıştır. İhtisasını ise, Amerika Birleşik Devletlerinde Connecticut eyaletindeki Yale Üniversitesi’ne bağlı Griffin Hastanesi’nde 1993 yılında tamamlayarak Dahiliye - İç Hastalıkları uzmanı olmuştur. Ayrıca Mount Sinai Tıp Fakültesi Hematoloji – Onkoloji Bilim Dalı Mount Sinai Tıp Fakültesi, New York, New York, ABD'de Tıbbi Onkoloji üzerine yan dal ihtisas eğitimini de tamamlamıştır. Marmara Üniversite Hastanesi Onkoloji Bilim Dalı'nda öğretim üyesi olarak görev yapmış olan Prof. Dr. Serdar Turhal, mesleki çalışmalarına şu an İstanbul'da bulunan özel muayenehanesi'nde devam etmektedir.
Makale

2016 – Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

Renal cell carcinoma (RCC) accounts for approximately 2% of all cancers.1 On admission, one-third of patients with RCC are at the metastatic stage.2 Chemotherapy resistance is very high in patients with RCC.3 Only a limited subset of patients ( 20%) benefit from cytokine therapy.4-7 It has been shown that the median progressionfree survival (PFS) was…

Devamını Oku
Makale

2015 – Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial)

Colorectal cancer is among the most common type of cancers worldwide. According to the GLOBOCAN 2008 database, which is published by the International Agency for Research on Cancer to estimate the worldwide incidence and mortality of 27 cancers from 182 countries, colorectal cancer (1.23 million, 9.7% of the total) is the third most commonly diagnosed…

Devamını Oku
Makale

2014 – Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients

Radical cystectomy with pelvic lymphadenectomy has been considered the standard treatment in muscle-invasive bladder cancer patients and 5-year overall survival rates are about 60 %.with this treatment [1] Alternatively, bladderpreserving strategies with maximal transurethral resection of bladder tumor followed by platinum-based chemoradiotherapy has been tested in randomized controlled trials [2–6]. In these studies, the complete…

Devamını Oku
Makale

2013 – Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients

Colorectal cancer is the fifth leading cause of cancer death worldwide [1] . Worldwide, colorectal cancer accounted for approximately 1.2 million new cancer cases in 2008 [2, 3] . Surgical resection is the only curative treatment for locoregional disease, but 40–50% of patients have recurrences and or metastasis and die of metastatic disease [4] .…

Devamını Oku
Makale

Böbrek Kanseri

Böbrekler kırmızı-kahverengi renkte ince bir kapsülle örtülü fasulye biçiminde iki organdır. Böbrekler karın üst bölgesinin arka kısmında bulunurlar. Sırt adaleleri ve alt kaburga kemiklerince dış etkilere karşı korunurlar. Böbrekler kandan artık ve zehirli maddeleri, fazla mineralleri ve suyu süzerek vücuttan dışarı çıkarırlar. İdrar böbrekler ile kandan süzülüp oluştuktan sonra üreter olarak adlandırılan içi boş idrar…

Devamını Oku
Makale

2012 – ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Colorectal cancer (CRC) is the most commonly diagnosed cancer in Europe and one of the leading causes of cancer death worldwide [1, 2]. In the past years treatment and outcome of early and advanced disease has steadily improved. Progress in imaging enables more precise differentiation of prognostic subgroups in rectal cancer and a selected treatment…

Devamını Oku